Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia signs agreement for new Covid-19 drug
Being trialled in the US, this drug is yet to gain approval from the regulatory authorities. The federal government of Australia has signed an agreement with pharma firm
Being trialled in the US, this drug is yet to gain approval from the regulatory authorities. The federal government of Australia has signed an agreement with pharma firm
Kite, a subsidiary of Gilead Sciences, has received the US Food and Drug Administration (FDA) approval for its Tecartus (brexucabtagene autoleucel) to treat patients with relapsed or refractory
As agreed, Merck’s subsidiary will commence a tender offer for the purchase of shares of Acceleron for $180 per share. Following completion of deal, this subsidiary of Merck
TRV027 is being evaluated as a potential therapy for treating acute lung injury that leads to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients suffering
AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m. Alexion had entered into a partnership with Caelum
Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir). Avigan/Reeqonus is a broad-spectrum oral antiviral, which is currently being assessed
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Saphnelo (anifrolumab) to treat adult patients with systemic lupus erythematosus (SLE). SLE is a serious autoimmune
UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China. Orismilast is a next-generation PDE4 inhibitor
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases. Axatilimab is an
Pfizer has dosed the first subjects in a Phase I clinical trial to test an influenza vaccine which is developed using mRNA technology. The randomised Phase I trial,